NEUROANATOMICAL BIOMARKERS OF EARLY AD
AD 早期的神经解剖学生物标志物
基本信息
- 批准号:6989343
- 负责人:
- 金额:$ 13.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-07-01 至 2010-06-30
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs diseaseapolipoprotein Ebioimaging /biomedical imagingbiomarkerbrain morphologycerebrospinal fluidcingulate gyrusclinical researchcognitioncomputational neurosciencedisease /disorder proneness /riskentorhinal cortexhippocampushuman middle age (35-64)human old age (65+)human subjectmagnetic resonance imagingneurochemistryneuropathology
项目摘要
Alzheimer's disease (AD) is the most common dementing illness of late life, and robs persons of vigorous activity and productivity in their later years. Future drug treatments may be capable of slowing the progression of the disease or even preventing its clinical appearance, and when such treatments become available, the ability to detect the illness in its earliest stages will be needed to take full advantage of them. The overall goal of this project is to test the use of structural magnetic resonance scanning and the tools of computational anatomy to distinguish nondemented subjects at elevated risk for developing dementia of the Alzheimer type (DAT) from age- and gender-matched comparison subjects. The primary strategy for identifying subjects at elevated risk for developing DAT will be having a parent with DAT; allelic status for the apolipoprotein E gene will be a secondary strategy. High resolution magnetic resonance (MR) scans will be collected from all subjects at entry into the study, and for subjects who are recruited during the first two years of the Project, repeat MR scans will be collected after three years. The specific aims of the project include a comparison of the structural characteristics of the hippocampus, parahippocampal gyrus (including the entorhinal cortex) and cingulate gyrus (anterior and posterior segments) in nondemented subjects with (N = 120) and without (n = 120) a parent with DAT. The total group of subjects will then be resorted according to the number of E4 alleles for apolipoprotein E, and a comparison of subjects with or without one or more E4 alleles will be made. If there are neuroanatomical differences in the groups of subjects with and without one or more E4 alleles, then the impact of the apoE4 allele on the effect of having
a parent with DAT will be investigated. In addition, we will determine whether there are correlations between neuroanatomical measures that discriminate between subjects at elevated risk for developing DAT and comparison subjects and other predictive variables assessed by other Projects.
阿尔茨海默病(AD)是最常见的老年痴呆症,剥夺了人们在晚年的剧烈活动和生产力。未来的药物治疗可能能够减缓疾病的进展,甚至阻止其临床表现,当这种治疗方法可用时,将需要在疾病的早期阶段检测疾病的能力,以充分利用它们。该项目的总体目标是测试使用结构磁共振扫描和计算解剖学工具来区分患阿尔茨海默型痴呆(DAT)风险升高的非痴呆受试者与年龄和性别匹配的对照受试者。鉴别发生DAT高风险受试者的主要策略是父母中有一方患有DAT;载脂蛋白E基因的等位基因状态将是次要策略。所有受试者在进入研究时将收集高分辨率磁共振(MR)扫描,对于在项目前两年招募的受试者,三年后将收集重复磁共振扫描。该项目的具体目标包括比较(N = 120)和(N = 120)父母患有DAT的非痴呆受试者(N = 120)海马、海马旁回(包括内嗅皮层)和扣带回(前段和后段)的结构特征。然后根据载脂蛋白E的E4等位基因的数量对受试者进行分组,并对有或没有一个或多个E4等位基因的受试者进行比较。如果在有或没有一个或多个E4等位基因的受试者组中存在神经解剖学上的差异,那么apoE4等位基因对具有的影响
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN G CSERNANSKY其他文献
JOHN G CSERNANSKY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN G CSERNANSKY', 18)}}的其他基金
Post-Graduate Research Training Aligned with the NIMH Strategic Plan
符合 NIMH 战略计划的研究生研究培训
- 批准号:
10115122 - 财政年份:2019
- 资助金额:
$ 13.98万 - 项目类别:
NEUROMORPHOMETRY IN SIBLINGS AT RISK FOR SCHIZOPHRENIA
对有精神分裂症风险的兄弟姐妹进行神经形态测量
- 批准号:
7476360 - 财政年份:2007
- 资助金额:
$ 13.98万 - 项目类别:
NEUROMORPHOMETRY IN SCHIZOPHRENIA BY COMPUTER ALGORITHM, ALZ BY BRAIN MAPPING
通过计算机算法进行精神分裂症的神经形态测量,通过脑图绘制 ALZ
- 批准号:
7420422 - 财政年份:2006
- 资助金额:
$ 13.98万 - 项目类别:
Stress, Glucocorticoids and Alzheimer Disease
压力、糖皮质激素和阿尔茨海默病
- 批准号:
7476278 - 财政年份:2005
- 资助金额:
$ 13.98万 - 项目类别:
Stress, Glucocorticoids and Alzheimer Disease
压力、糖皮质激素和阿尔茨海默病
- 批准号:
7676085 - 财政年份:2005
- 资助金额:
$ 13.98万 - 项目类别:
NEUROMORPHOMETRY IN SCHIZOPHRENIA BY COMPUTER ALGORITHM, ALZ BY BRAIN MAPPING
通过计算机算法进行精神分裂症的神经形态测量,通过脑图绘制 ALZ
- 批准号:
7182872 - 财政年份:2005
- 资助金额:
$ 13.98万 - 项目类别:
Stress, Glucocorticoids and Alzheimer Disease
压力、糖皮质激素和阿尔茨海默病
- 批准号:
6899584 - 财政年份:2005
- 资助金额:
$ 13.98万 - 项目类别:
Stress, Glucocorticoids and Alzheimer Disease
压力、糖皮质激素和阿尔茨海默病
- 批准号:
7116551 - 财政年份:2005
- 资助金额:
$ 13.98万 - 项目类别:
Stress, Glucocorticoids and Alzheimer Disease
压力、糖皮质激素和阿尔茨海默病
- 批准号:
7116719 - 财政年份:2005
- 资助金额:
$ 13.98万 - 项目类别:
Stress, Glucocorticoids and Alzheimer Disease
压力、糖皮质激素和阿尔茨海默病
- 批准号:
7277679 - 财政年份:2005
- 资助金额:
$ 13.98万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 13.98万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 13.98万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 13.98万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 13.98万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 13.98万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 13.98万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 13.98万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 13.98万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 13.98万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 13.98万 - 项目类别: